Skip to content

Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults with Refractory or Unexplained Chronic Cough

Refractory or Unexplained Chronic Cough

This is a phase 2b, randomized, double-blind, placebo-controlled study investigating the efficacy, safety, and tolerability of Taplucainium Inhalation Powder (NOC-110) once daily in adults with refractory or unexplained chronic cough.

null

Conditions de participation

  • Sexe:

    ALL
  • Âges admissibles:

    18 to 80

Critères de participation

Inclusion Criteria:

* Refractory or unexplained chronic cough for ≥ 12 months.
* Women of childbearing potential agree to follow the protocol specified contraceptive - guidance during the study.
* Males who are not vasectomized must agree to use the contraceptive methods defined in the protocol.
* Able to provide Informed Consent.

Exclusion Criteria:

* Previous exposure to taplucainium (formerly NTX-1175) or known allergy or hypersensitivity to taplucainium, its excipients/metabolites, or related compounds.
* Participants who are currently participating in another drug or device clinical study
* Participants who have participated in an Acute or Chronic Cough investigational study within 60 days before the start of the Screening.
* Current diagnosis of chronic obstructive pulmonary disease, bronchiectasis, unexplained pulmonary fibrosis, hemoptysis, bronchial asthma, or other pulmonary disease.
* Respiratory tract infection within 4 weeks of Screening or during screening period.
* Any female who is pregnant or lactating or wishing to become pregnant.
* Donation of \> 1 Unit (450 milliliter or more) of blood within 90 days prior to the first dosing.
* Alcohol or drug use disorder within the past 2 years.
* Current smoker/vaper or individuals who have given up smoking within the past 6 months, and/or those with \>20 pack-year smoking history.
* Current opiate/opioid use or medical history of opiate/opioid use disorder. History of concurrent malignancy or recurrence of malignancy in the last 2 years.
* Body Mass Index of ≥40 kg/m2.
* Positive results for human immunodeficiency virus, hepatitis B, or hepatitis C virus.
* Unable to refrain from the use of medications and treatments that can impact cough during the study.
* Have clinically significant history or evidence of poorly controlled cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological, immunological, or psychiatric disorder(s).

Lieu de l'étude

Recherche GCP Research
Recherche GCP Research
Montréal, Quebec
Canada

Contactez l'équipe d'étude

Primary Contact

Giuseppe Mazza

[email protected]
51478788915257
Inspiration Research Limited
Inspiration Research Limited
Toronto, Ontario
Canada

Contactez l'équipe d'étude

Primary Contact

Kenneth Chapman

[email protected]
4169449602
DIEX Recherche Victoriaville Inc.
DIEX Recherche Victoriaville Inc.
Victoriaville, Quebec
Canada

Contactez l'équipe d'étude

Primary Contact

Ethel Bellavance

[email protected]
8192601172
Clinique de pneumologie et du sommeil de Lanaudière
Clinique de pneumologie et du sommeil de Lanaudière
Saint-Charles-Borromee, Quebec
Canada

Contactez l'équipe d'étude

Primary Contact

Bonavuth Pek

[email protected]
4509163493
Dynamic Drug Advancement
Dynamic Drug Advancement
Ajex, Ontario
Canada

Contactez l'équipe d'étude

Primary Contact

George Philteos

[email protected]
9054273784
DIEX Recherche Sherbrooke Inc.
DIEX Recherche Sherbrooke Inc.
Sherbrooke, Quebec
Canada

Contactez l'équipe d'étude

Primary Contact

Ginette Girard

[email protected]
8193462887
Clinique Specialisee en Allergie de la Capitale
Clinique Specialisee en Allergie de la Capitale
Québec, Quebec
Canada

Contactez l'équipe d'étude

Primary Contact

Remi Gagnon

[email protected]
4187800881
McMaster University
McMaster University
Hamilton, Ontario
Canada

Contactez l'équipe d'étude

Primary Contact

Imran Satia

[email protected]
3658880571
Étude parrainée par
Nocion Therapeutics
Participants recherchés
Plus d'informations
ID de l'étude: NCT06504446